VAV1 gene mutations trigger T-cell tumors in mice

October 11, 2020

Tsukuba, Japan -- Life is an exquisite orchestration of growth and change, with checks and balances that fine-tune complex entwined interactions, both intrinsic and external. White blood cells (WBC) are integral to an organism's immune defenses against disease and invasion; unfortunately, these mechanisms may go awry causing uncontrolled increases in dysfunctional cell numbers, resulting in tumor formation. Now, researchers at the University of Tsukuba have illustrated how mutations in a specific gene called VAV1 may promote tumors involving a type of white blood cell, the T-cell, in experimental mice.

Leukocytes, or WBC, are fundamental to the body's immune function. They include B-lymphocytes that generate antibodies, as well as thymic-lymphocytes or T-cells with diverse immune-related functions, so called because they develop in the thymus gland. T-cell neoplasms include a mature subtype called peripheral T-cell lymphoma. Studies have shown that VAV1, a gene that participates in T-cell receptor signaling, is altered in several peripheral T-cell lymphoma variants; therefore, the research team sought to elucidate the role of VAV1 mutants in the malignant transformation of T-cells in vivo.

The tumor suppressor gene p53 is called 'guardian of the genome' because it prevents genome mutation. The researchers replicated VAV1 mutations found in human T-cell tumors in both normal ("wild-type") mice and mice lacking p53. Lead author Kota Fukumoto describes their findings: "No tumors developed in the wild-type mice with VAV1 mutations over a year of observation; whereas immature tumors developed in mice that lacked p53. Remarkably, mice that both lacked p53 and had mutations in VAV1 developed mature tumors resembling human peripheral T-cell lymphoma, and had poorer prognosis than the mice lacking p53 only."

The team also transplanted tumor cells into mice that lacked a functional thymus. The results suggested that tumor initiation was likely due to mechanisms within the cell itself. "We noted that T-cell tumors with VAV1 mutation showed Myc pathway enrichment, as well as somatic copy number alterations (SCNAs), including at the Myc locus," explains Professor Shigeru Chiba, senior author. Significantly, Myc, a family of regulator genes and proto-oncogenes, and SCNAs, which cause discrepancies in DNA copies, are both distinct hallmarks of tumor formation.

"Interestingly, pharmaceutical inhibition of the Myc pathway increased overall survival of mice harboring VAV1-mutant tumors," Professor Chiba adds. "Therefore, our methodology and results suggest that the VAV1-mutant expressing mice developed in this study could be a research tool for evaluating therapeutic agents directed against specific T-cell neoplasms."

University of Tsukuba

Related Mutations Articles from Brightsurf:

SARS-CoV-2 mutations do not appear to increase transmissibility
None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers, published in Nature Communications.

Predicting the evolution of genetic mutations
CSHL quantitative biologists have designed a new machine learning technique for predicting evolutionary pathways.

SNIPRs take aim at disease-related mutations
In a new study, lead author Alex Green, a researcher at the Biodesign Center for Molecular Design and Biomimetics and his colleagues describe a new method for detecting point mutations.

Cancer mutations occur decades before diagnosis
A large-scale pan-cancer analysis of the evolutionary history of tumours reveals that cancer-causing mutations occur decades before diagnosis.

Pinpointing rare disease mutations
Scientists have compiled mouse and human cell knockout data to categorise genes based on how essential they are for survival and organism development.

Using deep learning to predict disease-associated mutations
A research team led by Professor Hongzhe Sun from the Department of Chemistry at HKU, implemented a robust deep learning approach to predict disease-associated mutations of the metal-binding sites in a protein.

Cancer: The origin of genetic mutations
In the presence of some disruptive elements, cancer cells are unable to replicate its DNA optimally.

Mutations associated with sensitivity or resistance to immunotherapy in mNSCLC
The relationship between gene alterations and response to anti-PD-L1 with and without anti-CTLA-4 are not well characterized.

Machine learning for damaging mutations prediction
Scientists from Russia and India have proposed a novel machine-learning-based method for predicting damaging mutations in the protein atomic structure.

Discovery of new mutations may lead to better treatment
In the largest study to date on developmental delay, researchers analyzed genomic data from over 31,000 parent-child trios and found more than 45,000 de novo mutations, and 40 novel genes.

Read More: Mutations News and Mutations Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to